Development of a fluorescence polarization immunoassay for the routine detection of N-desmethylzopiclone in urine samples.
A polarization fluoroimmunoassay was developed for the detected of N-desmethylzopiclone in urine and the reagents were adapted for use on the Vitalab Eclair analyser. Therefore, N-fluoresceinthiocarbamyldesmethylzopiclone was synthesized as a fluorescent tracer and used in combination with an existing pool of antibodies, raised against the hemisuccinyl derivative of N-desmethylzopiclone. The optimization of the assay was performed on a semi-quantitative basis, relative to a cut-off value of 300 ng ml-1. No significant interference was observed from a selection of existing drugs and endogenous compounds. The minimum detectable dose of the immunoassay was calculated to be 30 ng ml-1 (pooled-variance t-distribution, p = 0.01, degrees of freedom = 10). Intra- and inter-assay relative standard deviations were < 10 and < 12%, respectively. For the confirmation of positive samples, an established reverse-phase HPLC technique, in combination with fluorescence detection, was used. The combined screening/confirmation procedure was applied to cumulative excretion samples, after ingestion of one tablet of Imovane (zopiclone, 7.5 mg).[1]References
- Development of a fluorescence polarization immunoassay for the routine detection of N-desmethylzopiclone in urine samples. Mannaert, E., Daenens, P. The Analyst. (1996) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
